169 related articles for article (PubMed ID: 25297731)
1. [Involvement of aberrant DNA methylation in hematological malignancies].
Matsui H
Rinsho Ketsueki; 2014 Oct; 55(10):1709-14. PubMed ID: 25297731
[No Abstract] [Full Text] [Related]
2. Connections between TET proteins and aberrant DNA modification in cancer.
Huang Y; Rao A
Trends Genet; 2014 Oct; 30(10):464-74. PubMed ID: 25132561
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics: reversible tags.
Wright J
Nature; 2013 Jun; 498(7455):S10-1. PubMed ID: 23803942
[No Abstract] [Full Text] [Related]
4. [Genome-wide analysis of AML and MDS].
Ogawa S
Nihon Rinsho; 2012 Apr; 70 Suppl 2():113-8. PubMed ID: 23133938
[No Abstract] [Full Text] [Related]
5. [The significance of the epigenetics modifying gene mutations in acute myeloid leukemia].
Wakita S; Yamaguchi H
Nihon Rinsho; 2014 Jun; 72(6):1026-32. PubMed ID: 25016799
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
7. Rethinking the gold standard for recurrent DNA mutations detection in acute myeloid leukemia.
Novaretti MC
Eur J Haematol; 2016 Feb; 96(2):109-10. PubMed ID: 26110968
[No Abstract] [Full Text] [Related]
8. Genetic and epigenetic alterations of myeloproliferative disorders.
Milosevic JD; Kralovics R
Int J Hematol; 2013 Feb; 97(2):183-97. PubMed ID: 23233154
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.
Reszka E; Jabłońska E; Wieczorek E; Valent P; Arock M; Nilsson G; Nedoszytko B; Niedoszytko M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803981
[TBL] [Abstract][Full Text] [Related]
10. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
11. [TET2 dysregulation in hematologic malignancies].
Sakata-Yanagimoto M
Rinsho Ketsueki; 2014 Oct; 55(10):1893-902. PubMed ID: 25297753
[No Abstract] [Full Text] [Related]
12. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies.
Li W; Xu L
Oncol Res Treat; 2019; 42(6):309-318. PubMed ID: 31055566
[TBL] [Abstract][Full Text] [Related]
13. DNA methyltransferases in hematological malignancies.
Hoang NM; Rui L
J Genet Genomics; 2020 Jul; 47(7):361-372. PubMed ID: 32994141
[TBL] [Abstract][Full Text] [Related]
14. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E; Kuismin O; Rajamäki K; Ristolainen H; Aavikko M; Kondelin J; Saarinen S; Berta DG; Katainen R; Hirvonen EAM; Karhu A; Taira A; Tanskanen T; Alkodsi A; Taipale M; Morgunova E; Franssila K; Lehtonen R; Mäkinen M; Aittomäki K; Palotie A; Kurki MI; Pietiläinen O; Hilpert M; Saarentaus E; Niinimäki J; Junttila J; Kaikkonen K; Vahteristo P; Skoda RC; Seppänen MRJ; Eklund KK; Taipale J; Kilpivaara O; Aaltonen LA
Nat Commun; 2019 Mar; 10(1):1252. PubMed ID: 30890702
[TBL] [Abstract][Full Text] [Related]
15. Interpreting new molecular genetics in myelodysplastic syndromes.
Abdel-Wahab O; Figueroa ME
Hematology Am Soc Hematol Educ Program; 2012; 2012():56-64. PubMed ID: 23233561
[TBL] [Abstract][Full Text] [Related]
16. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy.
Vasanthakumar A; Godley LA
Cancer Genet; 2015 May; 208(5):167-77. PubMed ID: 25892122
[TBL] [Abstract][Full Text] [Related]
17. A genome-scale map of DNA methylation turnover identifies site-specific dependencies of DNMT and TET activity.
Ginno PA; Gaidatzis D; Feldmann A; Hoerner L; Imanci D; Burger L; Zilbermann F; Peters AHFM; Edenhofer F; Smallwood SA; Krebs AR; Schübeler D
Nat Commun; 2020 May; 11(1):2680. PubMed ID: 32471981
[TBL] [Abstract][Full Text] [Related]
18. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.
Dobay MP; Lemonnier F; Missiaglia E; Bastard C; Vallois D; Jais JP; Scourzic L; Dupuy A; Fataccioli V; Pujals A; Parrens M; Le Bras F; Rousset T; Picquenot JM; Martin N; Haioun C; Delarue R; Bernard OA; Delorenzi M; de Leval L; Gaulard P
Haematologica; 2017 Apr; 102(4):e148-e151. PubMed ID: 28082343
[No Abstract] [Full Text] [Related]
19. Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?
Zebisch A; Hoefler G; Quehenberger F; Wölfler A; Sill H
Leukemia; 2013 Aug; 27(8):1777-8. PubMed ID: 23417030
[No Abstract] [Full Text] [Related]
20. Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia.
Ottone T; Cicconi L; Hasan SK; Lavorgna S; Divona M; Voso MT; Montefusco E; Melillo L; Barragán E; Platzbecker U; Giannì L; Hubmann M; Pagoni M; Amadori S; Lo-Coco F
Leuk Res; 2012 Apr; 36(4):474-8. PubMed ID: 22071137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
